您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > BML-190(Indomethacin morpholinylamide IMMA)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
BML-190(Indomethacin morpholinylamide IMMA)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
BML-190(Indomethacin morpholinylamide IMMA)图片
CAS NO:2854-32-2
规格:≥98%
包装与价格:
包装价格(元)
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议
1g电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)426.89
FormulaC23H23ClN2O4
CAS No.2854-32-2
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 22 mg/mL (51.5 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Other info

Chemical Name: 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-1-(4-morpholinyl)-ethanone

InChi Key: BJSDNVVWJYDOLK-UHFFFAOYSA-N

InChi Code: InChI=1S/C23H23ClN2O4/c1-15-19(14-22(27)25-9-11-30-12-10-25)20-13-18(29-2)7-8-21(20)26(15)23(28)16-3-5-17(24)6-4-16/h3-8,13H,9-12,14H2,1-2H3

SMILES Code: CC(N1C(C2=CC=C(Cl)C=C2)=O)=C(CC(N3CCOCC3)=O)C4=C1C=CC(OC)=C4

Synonyms

BML-190; IMMA; LM-4131; BML 190; LM4131; BML190; LM 4131; Indomethacin Morpholinylamide

实验参考方法
In Vitro

In vitro activity: BML-190 has 50-fold selectivity for CB2 receptors over CB1 receptors. In HEK-293 cells stably expressing the human CB2 receptor, BML-190 potentiates the forskolin-stimulated accumulation of cAMP. BML-190 reduces the basal levels of inositol phosphate production in cells expressing the CB2 receptor. 10 μM of BML-190 decreases inositol phosphates accumulation by 38%. BML-190 is an aminoalkylindole. BML-190 is found to yield at least 15 metabolic products. BML-190 diminishes LPS-induced NO and IL-6 production in a concentration-dependent manner. BML-190 also inhibits LPS-induced PGE2 production and COX-2 induction.


Cell Assay: In HEK-293 cells expressing human Cb2 receptor, BML-190 promoted the forskoline-stimulated accumulation of cAMP. BML-190 also reduced the basal level production of inositol phosphate the CB(2) receptor and 16z44-expressing cells.

In Vivo
Animal model
Formulation & Dosage
References

FEBS Lett. 2003 Feb 11;536(1-3):157-60; Eur J Pharm Sci. 2010 Sep 11;41(1):163-72.